Atreca, Inc. (BCEL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Atreca, Inc. (BCEL) trades at $0.09 with AI Score 43/100 (Grade C). Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for solid tumors. Market cap: $3.57M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for BCEL: BCEL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BCEL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BCEL: 2/3 scored disciplines lean bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Atreca, Inc. (BCEL) Healthcare & Pipeline Overview
Atreca, Inc. is a clinical-stage biotechnology company specializing in antibody-based immunotherapeutics for solid tumors, leveraging its proprietary discovery platform to develop novel treatments like ATRC-101, targeting unmet needs in ovarian, lung, colorectal, and breast cancers, and collaborating with Xencor and the Bill & Melinda Gates Medical Research Institute.
What Is the Investment Thesis for BCEL?
Atreca, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful clinical development and commercialization of its lead product candidate, ATRC-101, and other pipeline assets. A key value driver is the potential efficacy of ATRC-101 across multiple solid tumor types, as suggested by its in vitro reactivity with a majority of ovarian, lung, colorectal, and breast cancer samples. Upcoming clinical trial results for ATRC-101 will be a critical catalyst. Further growth may be driven by the advancement of APN-122597 and ATRC-501/MAM01. However, the company's negative profit margin of -12617.8% and gross margin of -819.6% highlight the significant financial risks associated with drug development. The company's success is also dependent on its ability to maintain and expand its collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
Based on FMP financials and quantitative analysis
BCEL Key Highlights
- Atreca, Inc. is a clinical-stage biopharmaceutical company focused on antibody-based immunotherapeutics.
- Lead product candidate ATRC-101 targets a novel mechanism of action and reacts with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples in vitro.
- Developing APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues.
- Developing ATRC-501/MAM01 for the prevention of malaria, in collaboration with the Bill & Melinda Gates Medical Research Institute.
- Profit margin is -12617.8% and gross margin is -819.6%.
Who Are BCEL's Competitors?
BCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| XNCR Xencor, Inc. | $20.45 | +8.72% | $1.52B | — |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCEL's Key Strengths?
- Proprietary antibody discovery platform.
- Novel mechanism of action of ATRC-101.
- Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
- Focus on unmet needs in solid tumor treatment.
What Are BCEL's Weaknesses?
- Clinical-stage company with no currently approved products.
- High reliance on the success of ATRC-101.
- Negative profit and gross margins.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive BCEL Stock Higher?
- Clinical trial data readouts for ATRC-101 in various solid tumor types.
- Potential regulatory milestones for ATRC-101, including breakthrough therapy designation.
- Advancement of APN-122597 and ATRC-501/MAM01 through preclinical and clinical development.
- Expansion of strategic partnerships and collaborations.
What Are the Key Risks for BCEL?
- Financial-distress signal — its Altman Z-Score of -37.57 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-83.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for ATRC-101 and other pipeline candidates.
- Regulatory hurdles and approval delays.
- Competition from established pharmaceutical companies with greater resources.
- Patent challenges and intellectual property disputes.
- High cash burn rate and need for additional financing.
What Are the Growth Opportunities for BCEL?
- Expansion of ATRC-101 Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for ATRC-101 to include a broader range of solid tumor types and patient populations. Positive clinical data from these trials could lead to accelerated regulatory approval and commercialization, potentially capturing a significant share of the oncology market. The timeline for this growth opportunity is dependent on the successful completion of ongoing and planned clinical trials, with potential for initial data readouts within the next 1-2 years.
- Advancement of APN-122597: The development of APN-122597, a receptor tyrosine kinase inhibitor, represents another growth avenue for Atreca. Successful preclinical and clinical development of this candidate could lead to a new treatment option for patients with tumors expressing the target receptor tyrosine kinase. The market size for targeted cancer therapies is substantial, and APN-122597 could capture a portion of this market if proven effective and safe. This is likely a 3-5 year outlook.
- Commercialization of ATRC-501/MAM01 for Malaria Prevention: Atreca's collaboration with the Bill & Melinda Gates Medical Research Institute to develop ATRC-501/MAM01 for malaria prevention presents a unique growth opportunity. Successful development and commercialization of this vaccine could address a significant unmet need in global health, particularly in regions with high malaria prevalence. The timeline for this opportunity is dependent on the successful completion of clinical trials and regulatory approvals, with potential for commercialization within the next 5-7 years.
- Strategic Partnerships and Collaborations: Atreca can further expand its pipeline and capabilities through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. These collaborations can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of Atreca's product candidates. The company's existing collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute demonstrate the potential of this growth strategy. Ongoing:
- Expansion of Discovery Platform: Atreca's proprietary discovery platform is a key differentiator and a source of future growth opportunities. By continuously investing in and expanding this platform, Atreca can identify and develop new antibody-based immunotherapeutics targeting a wider range of diseases. This platform could generate new product candidates and licensing opportunities, driving long-term growth for the company. Ongoing:
What Opportunities Does BCEL Have?
- Expansion of ATRC-101 clinical trials to additional tumor types.
- Advancement of APN-122597 and ATRC-501/MAM01 through clinical development.
- Further strategic partnerships and collaborations.
- Potential for breakthrough therapy designation for ATRC-101.
What Threats Does BCEL Face?
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from established pharmaceutical companies.
- Patent challenges and intellectual property disputes.
What Are BCEL's Competitive Advantages?
- Proprietary antibody discovery platform.
- Novel mechanism of action of ATRC-101.
- Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
What Does BCEL Do?
Atreca, Inc., founded in 2010 and based in San Carlos, California, is a clinical-stage biopharmaceutical company dedicated to developing antibody-based immunotherapeutics for a variety of solid tumor types. The company's core mission revolves around identifying and developing novel cancer treatments by leveraging its unique discovery platform, which allows for the isolation and characterization of antibodies directly from patients' immune responses. Atreca's lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target. Preclinical data indicates that ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients, suggesting broad potential applicability. Beyond ATRC-101, Atreca is also developing APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues, and ATRC-501/MAM01, which targets the circumsporozoite protein of Plasmodium falciparum for the prevention of malaria. The company has established strategic collaborations to expand its research and development capabilities. A collaboration and license agreement with Xencor, Inc. focuses on the research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Additionally, Atreca has a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for malaria prevention.
What Products and Services Does BCEL Offer?
- Discovers and develops antibody-based immunotherapeutics.
- Focuses on treating a range of solid tumor types.
- Develops ATRC-101, a monoclonal antibody with a novel mechanism of action.
- Develops APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues.
- Develops ATRC-501/MAM01 for the prevention of malaria.
- Collaborates with Xencor, Inc. for novel CD3 bispecific antibodies in oncology.
- Partners with the Bill & Melinda Gates Medical Research Institute for malaria prevention.
How Does BCEL Make Money?
- Develops and out-licenses antibody-based therapeutics.
- Generates revenue through research collaborations and licensing agreements.
- Aims to commercialize its own developed therapeutics.
What Industry Does BCEL Operate In?
Atreca operates within the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The market for cancer immunotherapies is experiencing rapid growth, driven by advances in understanding the role of the immune system in fighting cancer. Key trends include the development of personalized medicine approaches and the exploration of combination therapies. Atreca's focus on antibody-based immunotherapeutics positions it within this growing market, but the company faces competition from larger, more established players with greater resources.
Who Are BCEL's Key Customers?
- Patients with solid tumor cancers.
- Patients at risk of malaria.
- Pharmaceutical companies through licensing and collaboration agreements.
Company Profile
Atreca, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO John A. Orwin. BCEL has traded publicly since 2019.
F-Score 3/9Financial Health
Atreca, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -37.57 places it in the distress zone, a signal of elevated financial risk.
ROE -83%Key Financial Metrics
Return on equity for Atreca, Inc. stands at -83.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.7%, showing how much profit it generates from its asset base. A current ratio of 4.79 indicates the company holds enough short-term assets to cover its near-term obligations.
BCEL Valuation & Market Position
With a $3.57M market cap, Atreca, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BCEL's quantitative score of 43/100 is below the peer average of 74/100.
FY2026 estForward Outlook
Wall Street analysts project Atreca, Inc. revenue of about $303K for fiscal 2026, with EPS near $-0.75.
BCEL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Atreca's recent insider buying suggests those in the know see long-term potential, signaling confidence in the company's direction.
- The community's overall bullish sentiment indicates strong belief in Atreca's pipeline and future prospects, driving positive momentum.
- Market perception of Atreca as an innovator in cancer therapeutics is growing, attracting attention from investors seeking promising biotech ventures.
- Recent developments in their research programs are viewed optimistically, with potential for breakthroughs that could significantly impact the company's value.
Bear Case
- Lack of significant news in the past month has led to some community members questioning near-term catalysts for growth.
- Bearish sentiment within the community highlights concerns about the competitive landscape and the challenges of bringing novel therapies to market.
- Market perception acknowledges the high-risk nature of biotech investments, with skepticism surrounding Atreca's ability to navigate regulatory hurdles and secure funding.
- Recent insider selling, though potentially unrelated to company performance, has raised eyebrows and fueled some negative speculation within the community.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BCEL Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Sep 26, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 24, 2022
-
Stocks That Hit 52-Week Lows On Thursday
· Jul 29, 2021
BCEL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCEL.
Price Targets
Wall Street price target analysis for BCEL.
BCEL MoonshotScore
What does this score mean?
The MoonshotScore rates BCEL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John A. Orwin
CEO
John A. Orwin serves as the CEO of Atreca, Inc. His extensive background in the biopharmaceutical industry includes leadership roles at several prominent companies. Prior to joining Atreca, he held executive positions at Relypsa, Affymax, and Genentech. His experience spans various aspects of drug development and commercialization, including clinical trials, regulatory affairs, and market access. Orwin's expertise in building and scaling biopharmaceutical companies makes him well-suited to lead Atreca through its next phase of growth.
Track Record: Under John Orwin's leadership, Atreca has advanced its lead product candidate, ATRC-101, into clinical trials and established strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute. These achievements reflect his ability to drive innovation and build partnerships. He is responsible for managing 90 employees.
BCEL Healthcare Stock FAQ
What does the AI Score mean for BCEL?
BCEL holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for solid tumors. Their lead product candidate, ATRC-101, targets …
What does Atreca, Inc. do?
Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for the treatment of solid tumors. The company's core technology is its proprietary discovery platform, which allows for the identification and characterization of antibodies directly from patients' immune responses.
What do analysts say about BCEL stock?
Analyst coverage of Atreca, Inc. (BCEL) is limited, reflecting the company's early stage of development and market capitalization. Analyst ratings and price targets vary, but generally reflect cautious optimism regarding the potential of ATRC-101 and the company's discovery platform. Key valuation metrics include enterprise value and potential peak sales of ATRC-101.
What are the main risks for BCEL?
The main risks for Atreca, Inc. include clinical trial failures or delays, regulatory hurdles and approval delays, competition from established pharmaceutical companies, and patent challenges. As a clinical-stage company, Atreca is heavily reliant on the successful development and commercialization of its product candidates, particularly ATRC-101. Any setbacks in clinical trials or regulatory reviews could significantly impact the company's value.
How does Atreca, Inc. navigate regulatory approval processes?
Atreca, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by regulatory agencies such as the FDA. This involves comprehensive preclinical testing, well-designed clinical trials, and meticulous data collection and analysis. The company also engages in ongoing communication with regulatory agencies to address any concerns and ensure compliance.
What is the potential market opportunity for ATRC-101?
The potential market opportunity for ATRC-101 is substantial, given its broad reactivity with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples in vitro. These cancers represent significant unmet needs in oncology, with large patient populations and limited treatment options.
What are the key factors to evaluate for BCEL?
Atreca, Inc. (BCEL) holds an AI score of 43/100 (low). Not financial advice.
How frequently does BCEL data refresh on this page?
BCEL's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BCEL's recent stock price performance?
Atreca, Inc. (BCEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary antibody discovery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.